Approach:
For the shortlisting of potential in vitro diagnostics (IVD) manufacturers for acquisition or partnership opportunities, the process began with data collection on 320 U.S. and EU-based companies provided by the client. This was supplemented by a secondary search that accessed detailed information on 192 companies through reputable databases such as Biopharmguy, Dun & Bradstreet, PitchBook, CB Insights, SEC filings, and Craft.co. Companies were then filtered and shortlisted based on IVD sales criteria, specifically targeting those with annual revenues between $50 million and $800 million.
The focus was further refined to organizations with a product portfolio centered on biochemical and immunology/genetics segments, with established capabilities in both manufacturing and sales.
Each shortlisted company was rigorously evaluated against a comprehensive set of criteria, including revenue, gross margin, R&D expenditure, breadth of product offerings (number of assays, kits, devices, and reagents), therapeutic area coverage, geographic footprint, and sales channel effectiveness. This structured and data-driven approach ensured the identification of highly relevant and strategically aligned IVD manufacturers suitable for acquisition or partnership, aligning with the client’s growth and market expansion objectives.
Key findings:
Revenue is a crucial metric to assess a company’s market presence and capabilities, allowing prioritization of potential partners or acquisition targets. Companies with higher revenues generally demonstrate stronger market positions and are considered high-potential candidates for collaboration or evaluation. For example, Grifols (Spain) is classified as high potential due to its extensive product portfolio spanning immunohematology, infectious, autoimmune, and neurological diseases, along with a direct presence in 30 countries. Novacyt (UK) represents the medium potential segment, focusing on molecular and protein-based diagnostics and experiencing significant revenue growth driven by its COVID-19 product line. CerTest Biotec (Spain) falls into the low-potential category, specializing in PCR and antigen tests while actively working to expand into RNA vaccine development. This tiered classification enables targeted strategic engagement based on revenue strength and core capabilities.
Business Impact:
The report provided the client with vital insights into the IVD market landscape in Europe and the U.S., enhancing their understanding of key players, their strengths, and strategic tactics. This comprehensive market intelligence enabled the client to make informed decisions, better navigate competitive dynamics, and seize growth opportunities. By identifying and profiling potential acquisition or partnership candidates, the client gained a strategic pipeline aligned with their objectives. Detailed company assessments allowed for focused evaluation of market presence and capabilities, facilitating prioritization of collaborations that foster innovation and market expansion. Overall, the findings bolstered the client’s competitive position and supported strategic planning for sustained growth within the evolving IVD sector.